HSDD

AcronymDefinition
HSDDHypoactive Sexual Desire Disorder
HSDDHigh Speed Digital Design
HSDDHigh-Speed Digital Design
HSDDHistorical Stock Data Downloader (Semaj Software)
HSDDHardware/Software Design and Development (est. 1985; Brecksville, OH)
HSDDHigh School Drama Department
HSDDHealth Systems Development Division (Seychelles and Canada)
References in periodicals archive ?
With our deep relationships in the womens health community and experience building educational programs that engage patients and healthcare professionals, AMAG is well suited to drive awareness and increased understanding of HSDD.
Those in favor of approval said that the drug had only a modest beneficial effect in a controlled, limited population, but cited the unmet need for a treatment for HSDD. They strongly supported certification of prescribers to ensure the drug is used to treat the appropriate patients and that patients are fully counseled about the potential risks.
This finding has implications for the current DSM criteria used to diagnose HSDD, one of which specifies "...
"LibiGel remains the only product in the world in Phase III development for the treatment of HSDD," said Stephen M.
Currently, no drug is approved for HSDD, but testosterone and bupropion are used off-label for this indication.
Some research suggests 10 percent of women may suffer from HSDD.
In addition to psychological therapies (mindfulness), behavioral therapies (sensate focus), and cognitive-behavioral therapies (CBTs), a range of pharmacologic agents have been or are currently being used, often off-label, in the management of HSDD in women.
Biopharmaceutical company Palatin Technologies Inc (NYSE American:PTN) said on Monday that it has successfully filed its New Drug Application (NDA) for bremelanotide with the US Food and Drug Administration (FDA) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
today announced they have entered into an agreement for exclusive North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, that has successfully completed two Phase 3 trials.
At a joint meeting of two FDA advisory panels in June, members of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted 18-6 that the overall benefit-risk profile of flibanserin supported approval for treating hypoactive sexual desire disorder (HSDD) in premenopausal women, provided that some risk management conditions were met.
At a joint meeting of two Food and Drug Administration advisory panels in June, members of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted 18-6 that the overall benefit-risk profile of flibanserin supported approval for treating hypoactive sexual desire disorder (HSDD) in premenopausal women, provided that certain risk management options beyond labeling were implemented.
The testosterone transdermal patch improves hypoactive sexual desire disorder (HSDD) in postmenopausal women (strength of recommendation [SOR]: A, 2 randomized controlled trials [RCTs]).